Editas Medicine
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell EDIT and other ETFs, options, and stocks.About EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9).
CEOGilmore O’Neill
CEOGilmore O’Neill
Employees246
Employees246
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2013
Founded2013
Employees246
Employees246
EDIT Key Statistics
Market cap334.05M
Market cap334.05M
Price-Earnings ratio-1.30
Price-Earnings ratio-1.30
Dividend yield—
Dividend yield—
Average volume3.64M
Average volume3.64M
High today$4.34
High today$4.34
Low today$3.60
Low today$3.60
Open price$4.19
Open price$4.19
Volume3.53M
Volume3.53M
52 Week high$4.54
52 Week high$4.54
52 Week low$0.9101
52 Week low$0.9101
EDIT News
TipRanks 2d
Editas Medicine Unveils Promising Preclinical Data on EDIT-401Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 2d
Editas Medicine reports in vivo preclinical PoC data for EDIT-401Editas Medicine (EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, one-time therapy to significantly reduce LDL-cholestero...
Simply Wall St 5d
While institutions invested in Editas Medicine, Inc. benefited from last week's 11% gain, individual investors stood to gain the mostAdvertisement Key Insights The considerable ownership by individual investors in Editas Medicine indicates that they collectively have a greater say in manage...
Analyst ratings
43%
of 14 ratingsBuy
42.9%
Hold
42.9%
Sell
14.3%
People also own
Based on the portfolios of people who own EDIT. This list is generated using Robinhood data, and it’s not a recommendation.